The AI integration aims to expand nuclear energy use in maritime, including floating plants, offshore energy, and ship power. Credit: Lucid Catalyst. Lloyd’s Register (LR), a UK-based classification society, has collaborated with Microsoft to use generative AI to enhance the […]
Lloyd’s Register, Microsoft to advance AI-driven nuclear tech Read More »
Illuccix is used for PET imaging to detect PSMA-positive lesions in male prostate cancer patients. Credit: Korawat photo shoot/Shutterstock. Health Canada has expanded the approved use of Telix Pharmaceuticals’ Illuccix for patient selection in prostate-specific membrane antigen (PSMA) targeted radionuclide
Telix announces Canada approval for Illuccix label expansion Read More »
IntiQuan enhances PLG’s portfolio with advanced dose-response evaluations and proactive safety assessments. Credit: IM Imagery/Shutterstock. ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics. The move enhances PLG’s capabilities in drug development, focusing on
ProductLife enhances drug development with IntiQuan acquisition Read More »
The therapy modifies patients’ T cells to carry an anti-CD7 CAR and re-administers them. Credit: Kateryna Kon/Shutterstock. Singapore’s National University Health System (NUHS) has announced that a new cluster of differentiation (CD7) chimeric antigen receptor (CAR)-T cell therapy has demonstrated
CD7 CAR-T cell therapy shows promise for leukaemia Read More »
OKI-219 is in Phase I trials for solid tumours. Credit: Nemes Laszlo/Shutterstock. OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, with the combined entity set to operate under the OnKure Therapeutics name. The shares will commence
OnKure and Reneo Pharmaceuticals complete merger Read More »
mAbxience will create oncology biosimilars using its cGMP-certified plants in Spain and Argentina. Credit: Lightspring via Shutterstock. Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar
Teva and mAbxience partner to develop biosimilar candidate for oncology Read More »
CAD is a rare blood disorder where B cells produce antibodies that destroy red blood cells. Credit: Siwakorn TH via Shutterstock. Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo Read More »
BMS’ Opdivo is said to be the only PD-1 inhibitor to demonstrate an advantage over chemotherapy, both presurgery and in a perioperative setting. Credit: HJBC via Shutterstock. Bristol Myers Squibb (BMS) has received approval from the US Food and Drug
BMS receives FDA approval for Opdivo to treat NSCLC Read More »
The funding will enable Aralez Bio to enhance cGMP production capabilities by leveraging an advanced technology. Credit: National Resilience/Business Wire. National Resilience’s subsidiary Resilience Government Services has received around $17.5m in funding for expanding critical medicine components manufacturing. Resilience received
Resilience secures funds to enhance production of essential medicine components Read More »
Vevizye’s effectiveness in treating DED was confirmed by two placebo-controlled trials. Credit: fizkes via Shutterstock. Novaliq and Laboratoires Théa have announced approval from the European Commission (EC) for Vevizye (ciclosporin 0.1% eye drops solution) for patients with dry eye disease
Novaliq and Laboratoires Théa announce EC approval for dry eye disease therapy Read More »
